is a fully human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, and giant cell tumor of bone - In those with postmenopausal osteoporosis it decreases the risk of fractures but increases the risk of infection
The most common side effects are joint and muscle pain in the arms or legs. There is an increased risk of infections such as cellulitis,hypocalcemia (low blood calcium), hypersensitivity allergy reactions, and osteonecrosis of the jaw and atypical hip fractures. Increased rates of eczema and hospitalization due to infections of the skin. It has been proposed that the increase in infections under denosumab treatment might be connected to the role of RANKL in the immune system. RANKL is expressed by T helper cells, and is thought to be involved in dendritic cell maturation.
Vial
3727 EGP
is a fully human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, and giant cell tumor of bone - In those with postmenopausal osteoporosis it decreases the risk of fractures but increases the risk of infection
The most common side effects are joint and muscle pain in the arms or legs. There is an increased risk of infections such as cellulitis,hypocalcemia (low blood calcium), hypersensitivity allergy reactions, and osteonecrosis of the jaw and atypical hip fractures. Increased rates of eczema and hospitalization due to infections of the skin. It has been proposed that the increase in infections under denosumab treatment might be connected to the role of RANKL in the immune system. RANKL is expressed by T helper cells, and is thought to be involved in dendritic cell maturation.
Note: All the provided information about this drug does not substitute for consulting a doctor.